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The validity of pharmacoeconomic analyses relies on the
quality and appropriateness of the medical data sources
used. Randomized trials, meta-analyses, epidemiological
and observational studies will be presented and the pros
and cons discussed, with special emphasis on topics such
as internal and external validity, comparator treatments,
surrogate measures of outcome, assessment of adverse re-
actions, the place of diagnostics, and censored observa-
tions. Our own analyses, along with examples from the
literature, will be presented to describe the pitfalls en-
countered when using common medical data sources. We
aim firstly to sensitize the economist about shortcomings
when medical data are used for purposes they were not
originally collected for, and secondly to enable physicians
to critically assess pharmacoeconomic studies that are
based on empirical data.
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DECISION ANALYSIS IN CANCER THERAPY,
A NEW WAY FOR EVALUATION OUTCOMES 
WITH THE ANALYTIC HIERARCHY
PROCESS (AHP)
Reibnitz C, Silva, Saavedra M
School of Public Health, University of Bielefeld,
Bielefeld, Germany
The analytic hierarchy process (AHP) is a decision analysis
technique for evaluating complex multi-attributed alterna-
tives with conflicting objectives among one or more scores.
The AHP uses judgments from the decision maker and
hierarchical decomposition to derive a set of ratio-scaled
utility measures for decision alternatives. With the AHP,
there is no need to estimate a utility function explicitly,
because the AHP deals with stated preferences at each step.
The model may be used to give a stage 1 breast cancer pa-
tient the chance to discover the full extent and weight of
the decision for selecting breast cancer treatment, though
similar models could be built for any type of treatment
(e.g., cost-benefit analysis). The model allows for the opin-
ions of the physician and the legitimate concerns of the pa-
tient. Another problem inherent in the medical field is the
lag between new treatments and their long-term statistical
confirmation. For this reason, it is imperative that physi-
cian and patient alter relevant weights, given advance-
ments in medical knowledge, particular situational needs
and patient concerns. The issues of concern in the model
were identified as the total of psychological effects from
the treatment; expected length of time that the patient can
reasonably expect to live a normal life after a surgery deci-
sion is acted upon; the quality of preservation of the breast
tissue and surrounding structures; side effects which may
develop as a result of the surgery; and patient’s back-
ground, medical status, and cost. Though this model evalu-
ates general treatment options of surgical, non-surgical,
combination, or no treatment, specific alternatives of ther-
apies could also be analyzed.
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TREATMENT STRATEGIES
McGhan WF
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The objective of this workshop is to demonstrate how in-
teractive software programs are useful tools in healthcare
decision-making as well as educational tools on specific
diseases and the decision-making process. In this work-
shop, a specific disease, gastroesophageal reflux disease
(GERD), will be used as the example. Decision support
systems are tools that allow systematic approaches to deci-
sion-making under conditions of uncertainty. There are
four steps in decision system development: 1) to identify
and bound the decision problem, 2) to structure the deci-
sion problem over time, 3) to characterize the information
needed to structure the decision, and 4) to perform the
analysis to reveal the preferred course of action. In this
workshop, a decision tree analysis will be demonstrated.
The branches of the tree describing the clinical pathway
treatment options will be discussed. The decision nodes
(treatment options), probability nodes (healing rates), and
resulting outcomes will be demonstrated. Sensitivity analy-
sis (changing one variable, such as one of the costs, or
changing two or three variables at one time) will be dem-
onstrated. Interactive software programs have the addi-
tional benefit as educational tools to self-instruct on the
clinical issues of a specific disease. Attendees will see how
the use of photos, graphics, and dictionaries within the de-
cision support software program can enhance the value of
the program as a user-friendly educational tool.
TRACK 2: GUIDELINES AND STANDARDS
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